
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is poised to have a successful future due to their recent clearances from the FDA and completion of Phase I studies, reaffirming their potential to replicate a primary Phase IIb design and the positive current atmosphere in the psychedelics space. Despite potential concerns over functional unbinding and regulatory decisions for COMP360, GH Research has shown impressive efficacy and a significant sales opportunity, leading to a positive outlook and increased future potential for the company's stock.
Bears say
GH Research is a clinical-stage biopharmaceutical company with a single segment focusing on research and development of mebufotenin therapies for treatment-resistant depression (TRD). While the company has upcoming milestones in the second half of 2026 and a strong financial position, including a current cash balance of $362.7MM, GH Research's lead product candidate, GH001, is only in Phase 2b clinical trials, and the company faces potential challenges with enrollment targets and the need for a psychotherapist during treatment. Furthermore, the company has yet to expand its product candidates into other indications and formulations, and we will only receive updates on these potential developments once GH001's Phase 3 trial is underway.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares